{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000032","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.312164+00:00","generated_at":"2026-06-02T16:02:53.462526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Curis Q1 net loss $11.9M ($2.05/sh); cash $40.7M; topline AML data May 14","bullets":["Net loss $11.9M vs $11.6M Q1 2023; revenue $2.1M (Erivedge royalties) vs $2.3M.","Cash, equivalents and investments $40.7M as of March 31, 2024; expected to fund operations into 2025.","Topline clinical data from TakeAim Leukemia study (emavusertib monotherapy in R/R AML) to be released May 14, 2024.","Abstracts accepted for ASCO (May 31-Jun 4) and EHA (Jun 13-16); posters on FLT3m and mSF cohorts.","Updated data for R/R PCNSL and frontline AML triplet combo expected late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000032","json":"https://secwatch.observer/filing/0001108205-24-000032.json","markdown":"https://secwatch.observer/filing/0001108205-24-000032.md","text":"https://secwatch.observer/filing/0001108205-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/0001108205-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/cris-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:02:53.462526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57ede6b3636556c6d6627cd940072ee29836cff3","claim":"CURIS INC reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income net loss of $11.9 million or $2.05 per share on both a basic and diluted basis.","evidence_excerpt":"For the first quarter of 2024, Curis reported a net loss of $11.9 million or $2.05 per share on both a basic and diluted basis as compared to $11.6 million or $2.39 per share on both a basic and diluted basis, for the same period in 2023. Revenues for the first quarter of 2024 were $2.1 million as compared to $2.3 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/0001108205-24-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$2.1 million"},{"label":"Net income","value":"net loss of $11.9 million or $2.05 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}